BZYR
BURZYNSKI RESEARCH INSTITUTE INC
Key Financials
Revenue
$0
NaN%
Net Income
$-1386207
↓ 3.8%
Operating Income
$-1386207
↓ 3.8%
EPS (Diluted)
$-0.01
0.0%
Total Assets
$847.00
↓ 63.3%
Total Liabilities
$42484.00
↑ 54.9%
Shareholders' Equity
$-41637.00
↓ 65.7%
Cash & Equivalents
$847.00
↓ 35.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 5/12/2026 | View on SEC |
| 8-K | 4/23/2026 | View on SEC |
| 10-Q | 1/13/2026 | View on SEC |
| 10-Q | 10/14/2025 | View on SEC |
| 8-K/A | 9/11/2025 | View on SEC |
| 8-K | 7/24/2025 | View on SEC |
| 10-Q | 7/15/2025 | View on SEC |
| 10-K | 5/20/2025 | View on SEC |
| 10-Q | 1/13/2025 | View on SEC |
| 10-Q | 10/10/2024 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BZYR |
| Company Name | BURZYNSKI RESEARCH INSTITUTE INC |
| CIK | 724445 |
| Sector | In Vitro & In Vivo Diagnostic Substances |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | OTC |
| SIC Code | 2835 |
| SIC Description | In Vitro & In Vivo Diagnostic Substances |
| Entity Type | operating |
| Fiscal Year End | 0228 |
| State of Incorporation | DE |
| Phone | (713) 335-5697 |